Teva Submits Fremanezumab for FDA Approval
Key milestone reached for Teva to advance global fremanezumab program for the preventive treatment of migraine. Fremanezumab aims to address unmet need in migraine community, a disease with currently limited preventive therapeutic options.
A second CGRP monoclonal antibody is now awaiting FDA approval.
Source: Teva Announces Submission of Biologics License Application for Fremanezumab to the U.S. FDA